Clinical Trials Archive

A building with a stone facade displays a sign that reads
A Single-Blind Dose-Ranging Study in Subjects With Neurogenic Orthostatic Hypotension to Evaluate the Effect of CST-3056 on Symptoms and Signs of Orthostatic Hypotension
A building with a stone facade displays a sign that reads
A Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients With Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression
A building with a stone facade displays a sign that reads
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke
A building with a stone facade displays a sign that reads
Comparison of Phenobarbital Dosing Strategies in Patients with Alcohol Withdrawal Syndrome: A Retrospective Cohort Study
A building with a stone facade displays a sign that reads
A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors
A building with a stone facade displays a sign that reads
Post-market Safety and Effectiveness of the CORUS-LX System in Improving Lumbar Interbody Fusion Outcomes for the Treatment of Degenerative Lumbosacral Disc Disease.
A building with a stone facade displays a sign that reads
Post-market Safety and Effectiveness of the CORUS-LX System in Improving Lumbar Interbody Fusion Outcomes for the Treatment of Degenerative Lumbosacral Disc Disease.
A building with a stone facade displays a sign that reads
The Role of Phenobarbital Versus Benzodiazepines in Patients with Alcohol Withdrawal Syndrome: A Retrospective Cohort Study
A building with a stone facade displays a sign that reads
Evaluation of Four Factor-Prothrombin Complex Concentrate (4F-PCC) in patients with severe obesity versus non-obese patients in reversal of warfarin
A building with a stone facade displays a sign that reads
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)